Source: Cynata Therapeutics
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cynata Therapeutics (CYP) executes a manufacturing services agreement with FUJIFILM Cellular Dynamics (FCDI) for its Cymerus therapeutic mesenchymal stem cell products
  • The agreement sees FCDI undertaking the product’s technology transfer, process validation and manufacturing
  • The company says the new agreement leverages both its strong strategic relationship with FUJIFILM and its extensive experience in cell therapy manufacture at FCDI.
  • The execution of the deal triggers a 12-month extension of the current voluntary escrow over the 8.1 million shares FUJIFILM Corporation holds in Cynata
  • Cynata is up 4.17 per cent, trading at 50 cents at 11:00 am AEDT

Cynata Therapeutics (CYP) has penned a manufacturing services agreement with FUJIFILM Cellular Dynamics (FCDI) for its Cymerus therapeutic mesenchymal stem cell products.

Cymerus is a proprietary therapeutic stem cell platform technology which uses induced pluripotent stem cells and a precursor cell known as mesenchymoangioblast to manufacture cell therapy products at commercial scale, without the limitation of multiple donors.

The products are derived from induced pluripotent stem cells for clinical trials and commercial applications.

The contract was foreshadowed in September through a strategic partnership agreement between Cynata and FUJIFILM Corporation, FCDI’s parent company.

The agreement will see FCDI undertaking the product’s technology transfer, process validation and manufacturing.

Cynata’s existing contract manufacturer, Waisman Biomanufacturing, will continue to manufacture the product for Cynata’s current clinical trials, which will continue as planned.

Dr Kilian Kelly, Cynata’s Chief Operating Officer, said the new manufacturing services agreement leverages both its strong strategic relationship with FUJIFILM and the extensive experience in cell therapy manufacture at FCDI.

“Ultimately, we foresee FCDI manufacturing product for our growing pipeline of clinical trials in high value indications and potentially for commercial use,” said Dr Kelly.

“This provides a turn-key manufacturing solution that our future corporate partners may avail themselves of.”

The execution of the manufacturing services agreement triggers a 12-month extension of the current voluntary escrow over the 8.1 million shares FUJIFILM Corporation holds in Cynata.

Cynata was up 4.17 per cent, trading at 50 cents at 11:00 am AEDT.

CYP by the numbers
More From The Market Herald
Agrimin (ASX:AMN) - CEO, Mark Savich

" Agrimin (ASX:AMN) announces $7m cap raise

Following a trading halt earlier in the week, fertiliser development company Agrimin (ASX:AMN) has announced plans…

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows